Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14740338.2021.1955101 http://scihub22266oqcxt.onion/10.1080/14740338.2021.1955101 34264151!8330010!34264151     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34264151&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Expert+Opin+Drug+Saf 2021 ; 20 (11): 1451-1453 Nephropedia Template TP {{tp|p=34264151|t=2021. Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines |pdf=|usr=}}{{34264151}} gab.com Text Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines JO: Expert Opin Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=34264151 #FOAvip Introduction: Concerns about the increased risk of blood clots associated with the VAXZEVRIA (previously named Oxford-AstraZeneca COVID-19 vaccine) and Johnson & Johnson (Janssen) COVID-19 vaccines raises the question of the thrombotic safety of other COVID-19 vaccines such as Pfizer-BioNTech or Moderna, especially in younger women, who at the early stage of the pandemic was a priority group for vaccination. Methods: Using the US-based Vaccine Adverse Event Reporting System (VAERS) and the FDA Event Reporting System (FAERS), we retrieved cases of thrombosis following vaccinations or hormonal contraceptive use in women aged </= 50 years. We used the reporting odds ratio (ROR) as a disproportionality measure. Results: On 19 March 2021, out of 13.6 million women aged </= 50 exposed to at least one dose of Pfizer-BioNTech or Moderna COVID-19 vaccines in the US, only 61 cases were reported with a total of 68 thromboembolic events (1 case per 222,951 vaccinated). None of the thromboembolic events included in our analysis were disproportionally reported for the two COVID-19 vaccines. Conclusion: Our results do support that, when compared to hormonal contraceptive use, the mRNA vaccines do not show disproportional reporting of thromboembolic events in younger women. Twit Text FOAVip Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines ????Expert Opin Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=34264151 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34264151 #FOAvip English Wikipedia <ref>{{Cite pmid|34264151}}</ref> Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines #MMPMID34264151 Sessa M; Kragholm K; Hviid A; Andersen M Expert Opin Drug Saf 2021[Nov]; 20 (11): 1451-1453 PMID34264151show ga Introduction: Concerns about the increased risk of blood clots associated with the VAXZEVRIA (previously named Oxford-AstraZeneca COVID-19 vaccine) and Johnson & Johnson (Janssen) COVID-19 vaccines raises the question of the thrombotic safety of other COVID-19 vaccines such as Pfizer-BioNTech or Moderna, especially in younger women, who at the early stage of the pandemic was a priority group for vaccination. Methods: Using the US-based Vaccine Adverse Event Reporting System (VAERS) and the FDA Event Reporting System (FAERS), we retrieved cases of thrombosis following vaccinations or hormonal contraceptive use in women aged |2019-nCoV Vaccine mRNA-1273[MESH] |Adverse Drug Reaction Reporting Systems[MESH] |Age Factors[MESH] |BNT162 Vaccine[MESH] |COVID-19 Vaccines/administration & dosage/*adverse effects[MESH] |Contraceptives, Oral, Hormonal/adverse effects[MESH] |Female[MESH] |Hormonal Contraception/adverse effects[MESH] |Humans[MESH] |Middle Aged[MESH] |Risk Assessment[MESH] |Risk Factors[MESH] |Sex Factors[MESH] |Thromboembolism/*blood/diagnosis/epidemiology[MESH] |Treatment Outcome[MESH]Thromboembolic events in younger women exposed to Pfizer-BioNTech or M(epmc).pdf DeepDyve Pubget Overpricing